Private equity funds managed by Blackstone have entered into a definitive agreement to acquire contract research organization (CRO) Nucleus Network from Australian private equity firm Crescent Capital.
The value of the transaction was not disclosed. For its part, Melbourne-based Crescent Capital acquired Nucleus Network in 2018 from the Baker Heart and Diabetes Institute, an independent medical research institute, also for an undisclosed amount.
Nucleus Network conducts outsourced Phase I clinical trials -- the earliest-stage trials in humans -- for clients in the pharmaceutical and biotechnology industries. The company bills itself as Australia's largest CRO . . .
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
→ Access to the weekly AW Deal Watch by AW Research
Required for access to AW Research
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators